Medicare Fines Half of Hospitals for Readmitting Too Many Patients

Jordan Rau, Kaiser Health News
2020-11-02

Nearly half the nation’s hospitals, many of which are still wrestling with the financial fallout of the unexpected coronavirus, will get lower payments for all Medicare patients because of their history of readmitting patients, federal records show.

Here are the hospitals hit with readmissions penalties for 2021. You can filter by location, hospital name or year.
Download Historical Data
Download the 2021 Readmission Data (.csv)

The penalties are the ninth annual round of the Hospital Readmissions Reduction Program created as part of the Affordable Care Act’s broader effort to improve quality and lower costs. The latest penalties are calculated using each hospital case history between July 2016 and June 2019, so the flood of coronavirus patients that have swamped hospitals this year were not included.

The Centers for Medicare & Medicaid Services announced in September it may suspend the penalty program in the future if the chaos surrounding the pandemic, including the spring’s moratorium on elective surgeries, makes it too difficult to assess hospital performance.

For this year, the penalties remain in effect. Retroactive to the federal fiscal year that began Oct. 1, Medicare will lower a year’s worth of payments to 2,545 hospitals, the data show. The average reduction is 0.69%, with 613 hospitals receiving a penalty of 1% or more.

Out of 5,267 hospitals in the country, Congress has exempted 2,176 from the threat of penalties, either because they are critical access hospitals — defined as the only inpatient facility in an area — or hospitals that specialize in psychiatric patients, children, veterans, rehabilitation or long-term care. Of the 3,080 hospitals CMS evaluated, 83% received a penalty.

The number and severity of penalties were comparable to those of recent years, although the number of hospitals receiving the maximum penalty of 3% dropped from 56 to 39. Because the penalties are applied to new admission payments, the total dollar amount each hospital will lose will not be known until after the fiscal year ends on July 30.

“It’s unfortunate that hospitals will face readmission penalties in fiscal year 2021,” said Akin Demehin, director of policy at the American Hospital Association. “Given the financial strain that hospitals are under, every dollar counts, and the impact of any penalty is significant.”

The penalties are based on readmissions of Medicare patients who initially came to the hospital with diagnoses of congestive heart failure, heart attack, pneumonia, chronic obstructive pulmonary disease, hip or knee replacement or coronary artery bypass graft surgery. Medicare counts as a readmission any of those patients who ended up back in any hospital within 30 days of discharge, except for planned returns like a second phase of surgery.

A hospital will be penalized if its readmission rate is higher than expected given the national trends in any one of those categories.

The industry has disapproved of the program since its inception, complaining the measures aren’t precise and it unfairly punishes hospitals that treat low-income patients, who often don’t have the resources to ensure their recoveries are successful.

Michael Millenson, a health quality consultant who focuses on patient safety, said the penalties are a useful but imperfect mechanism to push hospitals to improve their care. The designers of the penalty system envisioned it as a way to neutralize the economic benefit hospitals get from readmitted patients under Medicare’s fee-for-service payment model, as they are otherwise paid for two stays instead of just one.

“Every industry complains the penalties are too harsh,” he said. “if you’re going to tell me we don’t need any economic incentives to do the right thing because we’re always doing the right thing — that’s not true.”

Is the role of pValue going the way of the dinosaur?

Statisticians want to abandon science’s standard measure of ‘significance’

Here’s why “statistically significant” shouldn’t be a stamp of scientific approval

BY BETHANY BROOKSHIRE 6:00AM, APRIL 17, 2019

https://www.sciencenews.org/article/statisticians-standard-measure-significance-p-values?tgt=nr

NICOLAS_/ISTOCK /GETTY IMAGES PLUS

Reimbursement for Healthcare Goods and Services. Time to look at it differently?

Looking for insight on new concepts in reimbursement, check out the upcoming Employer Provider Interface Council Conference

Managing Health Benefits in an Era of Change
1st Annual Conference
June 11, 2019

The inaugural conference program is intended to provide a multi-stakeholder forum to address how various healthcare organizations are evolving to new outcomes-driven initiatives and reimbursement models. National & Regional leaders will share insights & knowledge from their perspective. Attendees will gain a better understanding of success along with the barriers or problems surrounding the effective communication of the value associated with healthcare innovation to determine possible opportunities for stakeholders to develop tools and resources to address these issues in moving forward on making change happen.

MEETING LOCATION:
Rutgers, The State University of New Jersey
Earnest Mario School of Pharmacy
160 Frelinghuysen Road, Piscataway, New Jersey 08854

REGISTRATION LINK: https://epic.register-then-pay.com/

Investigators’ Meeting

The MedCom team is excited to be organizing the upcoming event for Biohaven and their CRO, Linical Accelovance. The team is organizing an exciting meeting that features leading edge presentations by thought leaders in the therapeutic area.

We are actively working with the participants and the property to get everyone registered and travel booked for the meeting. Really exciting project.

Changes in the composition of The Pharmaceutical Research and Manufacturers of America (PhRMA) membership

PhRMA ousts 22 drugmakers from ranks in membership change

Original Post by Ned Pagliarulo, BioPharma Dive

Dive Brief:

  • Amid an effort to revamp the drug industry’s image, PhRMA rolled out new membership criteria Tuesday aimed at blunting criticism the trade association had expanded to include companies that spent little on research and development.
  • Members will now be required to invest an average of $200 million per year and at least 10% of global sales into R&D, stricter standards that seven companies didn’t meet. PhRMA’s board of directors also voted to eliminate the “associate” member category, ousting another 15 drugmakers from its ranks.
  • Backlash against drugmakers like Marathon Pharmaceuticals — a now ex-associate member —  had seemed to belie the group’s messaging on bold scientific innovation and pioneering researchers toiling away in a lab.

Dive Insight:

Public and legislative outrage over rising drug prices has been felt across the entire biopharma industry. Lawmakers and prosecutors have cast a wide net, targeting smaller companies like Ariad Pharmaceuticals, specialty pharmas like Valeant, generic drugmakers and big pharmas like Eli Lilly.

But the heaviest criticism has fallen on companies which have bought up rights to older drugs only to sharply jack up the price, despite not investing much in R&D.

Think Martin Shrekli’s infamous 5,000% percent price hike for Daraprim (pyrimethamine), a generic treatment for toxoplasmosis that was no longer regularly produced. Or Marathon Pharmaceutical’s decision to price Emflaza (deflazacort) at $89,000 a year after winning U.S. approval for the decades-old steroid that is commonly available in other countries at a fraction of the price.

With its new membership criteria, PhRMA is seeking to align itself more exclusively with the kind of companies that spend big bucks on R&D. The changes help to reinforce the trade group’s message that the biopharma industry delivers innovative cures at great expense (implicitly justifying higher prices for novel drugs).

The changes go into effect immediately. Well-known names like Horizon Pharma, Mallinckrodt and Jazz Pharmaceuticals were among the 22 ousted companies.

A higher bar also means some smaller biotechs not usually associated with low research spending were shown the door.

The Medicines Company, which is developing a PCSK9 synthesis inhibitor, has spent an average of 71% of its product sales on R&D over the past three years, meeting PhRMA’s first criteria. But annual R&D spending averaged only $134 million, falling below the group’s threshold.

BioMarin Pharmaceutical, a drugmaker focused on rare diseases, was also removed from PhRMA’s membership.

Republican Healthcare Plan failed. What happens next?

Why do people feel the Republican Healthcare Plan to replace Obamacare failed? Data from a survey conducted at the end of March 2017 is presented below.

Now the question is, what will be done next?

[graphiq id=”8OoylDo2rwF” title=”Poll: Why Didn’t the Republican Health Care Plan Pass?” width=”600″ height=”573″ url=”https://w.graphiq.com/w/8OoylDo2rwF” ]

Affordable Care Act – What do people want?

There are many opinions and views on the ACA but there are two realities; costs are spiraling and and options are dwindling. Perhaps the “leaders” of the mess that is known otherwise as the US Congress could get actually get together and try to draft something that will truly address the needs of the USA. I suggest that we start with meaningful tort reform and address the reimbursement model.

The New York Times has a nice opinion piece on the currently available options. Click on the image below to go to the February 16, 2019 piece.

What are your thoughts?

Contact the MedCom Collaborative team to discuss how we can improve your medical communications efforts. We also partner with many organizations to help deliver quality educational content.

Feedback from our clients for the Sol-Gel Investigator’s Meeting.

Another Successful MedCom Collaborative Event

The MedCom Collaborative team was pleased to have the privilege to be selected as the meeting organizer for the Sol-Gel Technologies Investigator Meeting held in Dallas. The event was held on February 26 and 27 at the Grand Hyatt in the Dallas/Forth Worth International Airport. This meeting included ~80 participants. Presentations were done live, by web access and through using web browsers to demonstrate an eData system.

A note from our client is included below;

Hi Robert –

We received a very complimentary note from Sol-Gel this morning about the Investigator’s Meeting and wanted to thank you for once again doing a great job for our team.

JH